Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Price Target of $6.54 According to Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $6.54.

A number of research analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. TD Cowen lowered their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research note on Wednesday, June 17th. HC Wainwright increased their target price on Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, June 11th. BTIG Research restated a “buy” rating and set a $2.00 price target on shares of Humacyte in a research report on Wednesday, August 12th. Finally, Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. HBK Investments L P purchased a new position in shares of Humacyte during the second quarter valued at approximately $617,000. Miramontes Capital LLC bought a new position in Humacyte during the 2nd quarter valued at about $85,000. Alyeska Investment Group L.P. purchased a new stake in shares of Humacyte during the 2nd quarter valued at about $4,700,000. Beacon Pointe Advisors LLC purchased a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Humacyte during the 2nd quarter valued at about $180,506. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Performance

Humacyte stock opened at $0.52 on Wednesday. The firm’s fifty day moving average price is $0.62 and its 200-day moving average price is $0.78. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. The stock has a market cap of $144.87 million, a P/E ratio of -1.06 and a beta of 2.44. Humacyte has a fifty-two week low of $0.50 and a fifty-two week high of $2.55.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%.The company had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.04 million. On average, equities research analysts expect that Humacyte will post -0.4 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing and commercializing off-the-shelf, bioengineered human tissues for use in vascular repair and regenerative medicine. Its technology is based on human acellular tissue-engineered vessels, which are designed to provide durable vascular conduits without requiring a patient-specific donor vessel.

The company’s lead product, Symvess, is an acellular tissue-engineered vessel approved by the U.S. Food and Drug Administration for the treatment of extremity arterial injuries in adults when emergency vascular repair is needed and a suitable vein is unavailable or inappropriate.